• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHU Shuzhen, LI Weixia. Incentive measures for orphan drug R&D in several Asian countries and regions and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 125-128. DOI: 10.11665/j.issn.1000-5048.20140123
Citation: CHU Shuzhen, LI Weixia. Incentive measures for orphan drug R&D in several Asian countries and regions and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 125-128. DOI: 10.11665/j.issn.1000-5048.20140123

Incentive measures for orphan drug R&D in several Asian countries and regions and the enlightenment to China

More Information
  • Literature review and comparative analysis were employed in this study to summarize the incentivemeasures for facilitating orphan drugs R&D in Japan, South Korea and Taiwan region of China. It was found that the incentive strength in Japan was the greatest among the countries and region above, while those in South Korea and Taiwan region were relatively conservative. Yet all these incentives had promoted the development of orphan drugs and their successful implementation experience have provide suggestions for the establishment of incentive measures for facilitating orphan drugs R&D in China.
  • [1]
    张舵,王晓洁.罕见病发病率上升“孤儿药”产业亟待政策支持[N].中国医药报,2013-01-08(7).
    [2]
    MHLW.指定年度別の承認取得、開発、指定取消の状況[EB/OL].(2013-07-25)http://www.nibio.go.jp/shinko/s_jyokyo.html.
    [3]
    Song PP,Gao JJ,Inagaki Y,et al.Rare diseases,orphan drugs,and their regulation in Asia:Current status and future perspectives[J].Intractable Rare Dis Re,2012,1(1):3-9.
    [4]
    邵建国.亚洲:“孤儿药”的乐土[N].医药经济报,2007-05-14(3).
    [5]
    Lee S,Lee JI.Rare disease research and orphan drug development[J].Kor J Clin Pharm,2013, 23(1):8-9.
    [6]
    How specific legislation for rare diseases and orphan drugs is changing life for some patients in Taiwan[EB/OL].http://www.orpha.net/actor/EuropaNews/2009/doc/Taiwan.pdf
    [7]
    Department of Health,TAIWAN.List of Orphan Drug[EB/OL].[2012-01-31].http://www.doh.gov.tw.
    [8]
    Tao Y,Bu YF,Zhang C,et al.Orphan drug management systems in Japan(日本的罕用药管理制度)[J].Chin Pharm J(中国药学杂志),2002,37(6):468-471.
    [9]
    Gong SW. Management strategies of improving orphan drugs accessibility in China(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
    [10]
    Tang JY,Zhao XY.Contrastive analysis of abroad orphan drug management systems and suggestions for China [J].Chin New Drug J(中国新药杂志),2013, 22(14):1 638-1 642.
    [11]
    Xin XX,Guan XD,Chen J,et al.Analysis and comparison of foreign and domestic orphan drug registration policies [J].Chin Pharm J(中国药学杂志),2013,48(15):1 323-1 327.
    [12]
    Cheng Y.The Dilemma and outlet of the legal institution of rare disease [J].Hebei Law Sci(河北法学),2011,29(5):10-17.
    [13]
    Wu SY, Zhang K. Opportunities and challenges in strategies establishement of rare disease research and prevention in China(中国建立罕见病研究和防治策略的机遇与未来挑战)[J].Shanghai Med Pharm J(上海医药),2011,32(10):502-504.
    [14]
    李天舒.“孤儿药”研发困境等待破局[N].健康报,2011-10-25(5).
  • Related Articles

    [1]CHEN Ye, DING Jinxi, LIU Ting, TANG Di, WU Fang, WU Liping, DUAN Wanting, XU Yangyan. Status, problems and improvement measures of health insurance reimbursement of national negotiated drugs used in outpatients[J]. Journal of China Pharmaceutical University, 2020, 51(5): 628-634. DOI: 10.11665/j.issn.1000-5048.20200516
    [2]YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
    [3]WANG Ennan, CHEN Yi, CHU Shuzhen. Comparison of Sino-Japanese innovative drug market access policy environment and enlightenment to China[J]. Journal of China Pharmaceutical University, 2017, 48(6): 745-750. DOI: 10.11665/j.issn.1000-5048.20170618
    [4]DING Zhichen, WEI Guan, DING Jinxi. Orphan drug regime in Japan and enlightenment on China:based on evaluation of orphan drug access in Japan[J]. Journal of China Pharmaceutical University, 2014, 45(1): 118-124. DOI: 10.11665/j.issn.1000-5048.20140122
    [5]DING Jinxi, LIU Weijing, LI Wei, LIU Yangyang, BAI Gengliang. Analysis of orphan drug accessibility and marketing authorization system in China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 111-117. DOI: 10.11665/j.issn.1000-5048.20140121
    [7]Preparation,in vivo and in vitro study of dipyridamole-loaded sustained-release dripping pills[J]. Journal of China Pharmaceutical University, 2008, 39(1): 64-67.

Catalog

    Article views (1124) PDF downloads (1896) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return